Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose influenza vaccine in elderly adults
NCT07327398Phase 2Not yet recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Quadrivalent influenza virus split vaccine (Zhifei Longcom) in influenza (2 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoints: Seroconversion rate at 30 days, Ratio of subjects with antibody titer ≥1:40 at 30 days and 2 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Quadrivalent influenza virus split vaccine (Zhifei Longcom)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07327398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327398.